Hydroxocobalamin
Alternative Names: AST-726Latest Information Update: 30 Oct 2021
At a glance
- Originator Ariston Pharmaceuticals
- Developer TG Therapeutics Inc
- Class Corrinoids; Vitamin B12 analogues; Vitamins
- Mechanism of Action Vitamin B 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine; Vitamin deficiency
Most Recent Events
- 07 Mar 2014 Discontinued - Phase-I for Vitamin deficiency in USA (Intranasal)
- 07 Mar 2014 Discontinued - Phase-II for Migraine in European Union (Intranasal)
- 08 Nov 2010 Manhattan Pharmaceuticals receives a Qualifying Therapeutic Discovery Project grant from the US Government for AST 726 development in Vitamin deficiency